pubs.acs.org/acsmedchemlett
ACKNOWLEDGMENT We thank Joan Murphy and Dr. Charles
(14) Duplantier, A. J.; Efremov, I.; Candler, J.; Doran, A. C.; Ganong,
A. H.; Haas, J. A.; Hanks, A. N.; Kraus, K. G.; Lazzaro, J. T.; Lu, J.;
Maklad, N.; McCarthy, S. A.; O'Sullivan, T. J.; Rogers, B. N.;
Siuciak, J. A.; Spraklin, D. K.; Zhang, L. B. 3-Benzyl-1,3-oxazoli-
din-2-ones as mGluR2 positive allosteric modulators: Hit-to lead
and lead optimization. Bioorg. Med. Chem. Lett. 2009, 19, 2524.
(15) Tresadern, G.; Cid, J. M.; Macdonald, G. J.; Vega, J. A.; de Lucas,
A. I.; Garcia, A.; Matesanz, E.; Linares, M. L.; Oehlrich, D.;
Lavreysen, H.; Biesmans, I.; Trabanco, A. A. Scaffold hopping
from pyridones to imidazo [1, 2-a] pyridines. New positive
allosteric modulators of metabotropic glutamate 2 receptor.
Bioorg. Med. Chem. Lett. 2009, 175.
Ross III for HR-MS analysis.
REFERENCES
(1)
Regier, D. A.; Narrow, W. E.; Rae, D. S.; Manderscheid, R. W.;
Locke, B. Z.; Goodwin, F. K. The de Facto US Mental and
Addictive Disorders Service System: Epidemiologic Catch-
ment Area Prospective 1-Year Prevalence Rates of Disorders
and Services. Arch. Gen. Psychiatry 1993, 50, 85.
(2)
(3)
(4)
(5)
Tandon, R.; Keshavan, M. S.; Nasrallah, H. A. Schizophrenia,
“Just the Facts”: what we know in 2008 part 1: overview.
Schizophr. Res. 2008, 100, 4.
Tandon, R.; Keshavan, M. S.; Nasrallah, H. A. Schizophrenia,
“just the facts” what we know in 2008. 2. Epidemiology and
etiology. Schizophr. Res. 2008, 102, 1.
Murphy, B. P.; Chung, Y. C.; Park, T. W.; McGorry, P. D. Pharma-
cological treatment of primary negative symptoms in schizo-
phrenia: a systematic review. Schizophr. Res. 2006, 88, 5.
Lieberman, J. A.; Stroup, T. S.; McEvoy, J. P.; Swartz, M. S.;
Rosenheck, R. A.; Perkins, D. O.; Keefe, R. S.; Davis, S. M.;
Davis, C. E.; Lebowitz, B. D.; Severe, J.; Hsiao, J. K. Effective-
ness of antipsychotic drugs in patients with chronic schizo-
phrenia. N. Engl. J. Med. 2005, 353, 1209.
(16) Fraley, M. E. Positive allosteric modulators of the metabotropic
glutamate receptor 2 for the treatment of schizophrenia. Expert
Opin. Ther. Pat. 2009, 19, 1259 and references therein.
(17) Pin, J. P; Parmentier, M. L.; Prezeau, L. Positive Allosteric
Modulators for γ-Aminobutyric AcidB Receptors Open New
Routes for the Development of Drugs Targeting Family 3 G-
Protein-Coupled Receptors. Mol. Pharmacol. 2001, 60, 881.
(18) Brnardic, E. J.; Fraley, M. E.; Garbaccio, R. M.; Layton, M. E.;
Sanders, J. M.; Culberson, C.; Jacobson, M. A.; Magliaro, B. C.;
Hutson, P. H.;O'Brien, J. A.;Huszar, S. L.;Uslaner, J. M.;Fillgrove,
K. L.; Tang, C.; Kuo, Y.; Sur, S. M.; Hartman, G. D. 3-Aryl-5-
phenoxymethyl-1, 3-oxazolidin-2-ones as Positive Allosteric
Modulators of mGluR2 for the Treatment of Schizophrenia:
Hit-to-Lead Efforts. Bioorg. Med. Chem. Lett. 2010, 3129.
(19) Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward,
K. W.; Kopple, K. D. Molecular properties that influence the oral
bioavailability of drug candidates. J. Med. Chem. 2002, 45, 2615.
(20) Benigni, F.; Trevisan, L. Synthesis of a new nitrogenous
heterocycle, 2H,3H-benzimidazo[1,2-b]oxazole. Farmaco,
Edizione Scientifica 1974, 12, 936.
(21) Bell, T. W.; Hu, L. Y.; Patel, S. V. Alkylation of heteroaryl halides
by 2:1 Grignard reagent/copper(I) mixtures. Synthesis of alky-
lated octahydrodibenzo[b,j][1,10]phenanthrolines. J. Org. Chem.
1987, 52, 3847.
(22) Tanaka, H.; Shishido, Y. Synthesis of aromatic compounds con-
taining a 1,1-dialkyl-2-trifluoromethyl group, a bioisostere of the
tertalkyl moiety. Bioorg. Med. Chem. Lett. 2007, 17, 6079.
(23) Pinkerton, A. B.; Vernier, J.-M.; Schaffhauser, H.; Rowe, B. A.;
Campbell, U. C.; Rodriguez, D. E.; Lorrain, D. S.; Baccei, C. S.;
Daggett, L. P.; Bristow, L. J. Phenyl-tetrazolyl acetophenones:
discovery of positive allosteric potentiatiors for the meta-
botropic glutamate 2 receptor. J. Med. Chem. 2004, 47, 4595.
(24) Galici, R.; Echermendia, N. G.; Rodriguez, A. L.; Conn, J. P.
A Selective Allosteric Potentiator of Metabotropic Glutamate
(mGlu) 2 Receptors Has Effects Similar to an Orthosteric
mGlu2/3 Receptor Agonist in Mouse Models Predictive of
Antipsychotic Activity. J. Pharmacol. Exp. Ther. 2005, 315, 1181.
(25) Galici, R.; Jones, C. K.; Hemstapat, K.; Nong, Y.; Echemendia,
N. G.; Williams, L. C.; de Paulis, T.; Conn, J. P. Biphenyl-indanone
A, a Positive Allosteric Modulator of the Metabotropic Glutamate
Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like
Effects in Mice. J. Pharmacol. Exp. Ther. 2006, 318, 173.
(6)
(7)
Chavez-Noriega, L. E.; Schaffhauser, H.; Campbell, U. C.
Metabotropic Glutamate Receptors: Potential Drug Targets
for the Treatment of Schizophrenia. Curr. Drug Targets: CNS
Neurol. Dis. 2002, 1, 261.
Carmell, J.; Perry, K. W.; Salhoff, C. R.; Monn, J. A.; Schoepp,
D. D. The Potent, Selective mGlu2/3 Receptor Agonist
LY379268 Increases Extracellular Levels of Dopamine, 3,4-
Dihydroxyphenylacetic Acid, Homovanillic Acid, and 5-Hy-
droxyindole-3-Acetic Acid in the Medial Prefrontal Cortex of
the Freely Moving Rat. J. Neurochem. 2000, 75, 1147.
Macek, T. A.; Winder, D. G.; Gereau, R. W.; Ladd, C. O.; Coon,
P. J. Differential involvement of group II and group III mGluRs
as autoreceptors at lateral and medial perforant path syna-
pse. J. Neurophysiol. 1996, 76, 3798.
Patil, S. T.; Zhang, L.; Martenyi, F.; Lowe, S. L.; Jackson, K. A.;
Andreev, B. V.; Avedisova, A. S.; Bardenstein, L. M.; Gurovich,
I. Y.; Morozova, M. A.; Mosolov, S. N.; Neznanov, N. G.; Reznik,
A. M.; Smulevich, A. B.; Tochilov, V. A.; Johnson, B. G.; Monn,
J. A.; Scheopp, D. D. Activation of mGlu2/3 receptors as a new
approach to treat schizophrenia: a randomized Phase 2
clinical trial. Nat. Med. 2007, 13, 1102.
(8)
(9)
(10) Wooley, M. L.; Pemberton, D. J.; Bate, S.; Corti, C.; Jones, D. M.
The mGlu2 but not the mGlu3 receptor mediates the actions of
the mGluR2/3 agonist, LY379268, in mouse models predictive
of antipsychotic activity. Psycopharmacology 2008, 196, 431.
(11) Fell, M. J.; Svensson, K. A.; Johnson, B. G.; Schoepp, D. D.
Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not
mGlu3 Receptors in the Preclinical Antipsychotic Pharmaco-
logy of the mGlu2/3 Receptor Agonist (-)-(1R,4S,5S,6S)-4-
Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid
(LY404039). J. Pharmacol. Exp. Ther. 2008, 326, 209.
(26) Rorick-Kehn, L. M.; Johnson, B. G.; Knitowski, K. M.; Salhoff,
C. R.; Witkin, J. M.; Perry, K. W.; Griffey, K. I.; Tizzano, J. P.;
Monn, J. A.; McKinzie, D. L.; Schoepp, D. D. In vivo pharmaco-
logical characterization of the structurally novel, potent, selec-
tive mGlu2/3 receptor agonist LY404039 in animal models of
psychiatric disorders. Psychopharmacology 2007, 193, 121.
(12) Conn, J. P.; Chirstopolous, A.; Lindsley, C. W. A Novel Selective
Positive Allosteric Modulator of Metabotropic Glutamate Recep-
tor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects
in Rat Behavioral Models. Nat. Rev. Drug Discovery 2009, 8, 41.
(13) Cube, R. V.; Vernier, J. M.; Hutchinson, J. H.; Gardner, M. F.; James,
J. K.; Rowe, B. A.; Schaffhauser, H.; Daggett, L.; Pinkerton, A. B.
3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phe-
noxy]butoxy}phenyl)propanoic acid: a brain penetrant allosteric
potentiator at the metabotropic glutamate receptor 2 (mGluR2).
Bioorg. Med. Chem. Lett. 2005, 14, 2389 and references therein.
r
2010 American Chemical Society
410
DOI: 10.1021/ml100115a ACS Med. Chem. Lett. 2010, 1, 406–410
|